RECRUITING

Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Many individuals develop dementia, and dementia has multiple causes, yet we currently have limited treatment options. A critical observation of the effectiveness of the available dementia treatments is that they tend to be more effective when started early. Previous studies have shown that multimodal lifestyle interventions can significantly delay the onset of Alzheimer's dementia in individuals with high risk for Alzheimer's or with Mild Cognitive Impairment (MCI). These interventions may be less effective when initiated after dementia has already been diagnosed or is more advanced. This study has two primary goals. The first goal is to assess attitudes around dementia risk for participants throughout the study as they learn of their personalized risk and possible lifestyle factors that may modify that risk. The second goal is to serve as a logistical pilot for the implementation of data collection and processing and multimodal lifestyle intervention to reduce the risk factors of dementia in individuals without current cognitive impairment but who are at high risk of progression to dementia. Secondary goals of this study include better defining what factors contribute the most risk to dementia and identifying sub-types of dementia defined by different genetic and molecular risk factors.

Official Title

Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study

Quick Facts

Study Start:2025-05-02
Study Completion:2026-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07146412

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:65 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults 65-75 years of age at enrollment with at least one self-reported 1st-degree relative who had or has any kind of dementia
  2. * Montreal Cognitive Assessment (MoCA) score \> 24 at initial enrollment
  3. * Able and willing to comprehend and sign the informed consent document
  4. * Able and willing to perform required physical performance tests
  5. * Able and willing to provide the study's minimum samples
  6. * Able and willing to conduct the study's minimum procedures
  7. * Able and willing to complete surveys, cognitive assessments, and questionnaires in English only
  8. * Has or has ready access to a PC, tablet, or smartphone with an internet connection required for procedures that they consent to
  1. * A diagnosis of cognitive impairment of any kind, including Alzheimer's disease, mild cognitive impairment, or any other diagnosis of dementia
  2. * If a subject is found to have cognitive impairment at initial enrollment (Montreal Cognitive Assessment (MoCA) score\<25), they will be excluded from the study
  3. * Self-reported pregnancy
  4. * Children under 19 years of age
  5. * Individuals not fluent in written and spoken English
  6. * Self-reported chronic or end-stage disease that would interfere with their participation in the study
  7. * Hospitalization for any reason in the past 3 months
  8. * Severe hearing and visual impairment that would interfere with the ability to complete study measures
  9. * Any other vulnerable subject at the time of enrollment as specified above

Contacts and Locations

Study Contact

Jesse N Cochran, PhD
CONTACT
256-327-5262
ncochran@hudsonalpha.org

Study Locations (Sites)

Smith Family Clinic for Genomic Medicine
Huntsville, Alabama, 35806
United States

Collaborators and Investigators

Sponsor: HudsonAlpha Institute for Biotechnology

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-02
Study Completion Date2026-04-30

Study Record Updates

Study Start Date2025-05-02
Study Completion Date2026-04-30

Terms related to this study

Keywords Provided by Researchers

  • alzheimer
  • cognitive impairment
  • APOE
  • PRS
  • pTau217

Additional Relevant MeSH Terms

  • Cognitive Impairment
  • Alzheimer Blood Biomarkers
  • Alzheimer Disease (AD)
  • Mild Cognitive Impairment (MCI)